Telix Pharmaceuticals Reports 56% Revenue Growth in 2025, Issues Strong 2026 Guidance

Telix Pharmaceuticals Limited announced its financial results for the year ended December 31, 2025, reporting revenue of US$803.8 million, up 56% year-over-year and achieving its upsized full-year guidance. The radiopharmaceutical company's shares climbed nearly 15% following the earnings release, as the results demonstrated strong commercial momentum driven by its precision medicine portfolio.

The Precision Medicine segment was a key growth driver, with revenue up 22% year-over-year, fueled by continued increases in Illuccix volumes and the successful U.S. launch of Gozellix, its second prostate cancer imaging agent. Gozellix benefited from Medicare reimbursement that took effect in October 2025. The segment's adjusted EBITDA rose 24% year-over-year to US$216.4 million, while gross margin remained stable at 64%. Q4 2025 group revenue reached approximately US$208 million, up about 46% from the prior year period.

Telix invested US$157.1 million in research and development for late-stage therapeutics and precision medicine pipeline assets during 2025. The company achieved adjusted EBITDA of US$39.5 million for the full year, reflecting increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and R&D. Selling and marketing expenses totaled US$82.4 million, reflecting incremental investment in global commercial infrastructure for new product launches.

The company's Telix Manufacturing Solutions segment includes RLS Radiopharmacies, IsoTherapeutics, and production facilities in Sacramento, Brussels, North Melbourne, and Yokohama. RLS reported US$238.4 million of total segment revenue, which includes US$170.1 million from third-party product sales and service fees. RLS transitioned to a positive adjusted EBITDA contribution of US$1.2 million.

For 2026, management guided for group revenue between US$950 million and US$970 million, implying mid-teens growth on top of 2025's strong base and reflecting continued uptake of Illuccix and Gozellix plus geographic expansion. The company ended 2025 with a cash balance of US$141.9 million following US$246.4 million of strategic investments and cash generated from operating activities of US$34.5 million.

On the regulatory front, Telix has filed a marketing authorization application for TLX101-Px (Pixclara) in Europe, concurrent to finalizing the New Drug Application package for the U.S. FDA. The company also believes it has aligned with the FDA on key outstanding issues for the TLX250-Px (Zircaix) Biologics License Application resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production.

In its therapeutics pipeline, Telix completed target enrollment for Part 1 of the ProstACT Global Phase 3 study in metastatic castration-resistant prostate cancer. The company received regulatory approval to commence LUTEON, a global Phase 2/3 monotherapy trial in metastatic clear cell renal cell carcinoma, as well as the IPAX-BrIGHT pivotal trial of TLX101-Tx in recurrent glioblastoma. Additionally, regulatory approval was granted for AlphaPRO, a Phase 1 first-in-human study of Telix's targeted alpha therapy candidate TLX592-Tx in advanced mCRPC, and ALPHIX, a Phase 1 study of TLX252-Tx for advanced metastatic kidney cancer.

Despite the strong revenue growth, profitability remained modest. Telix posted 2025 operating income of about US$19 million, down from roughly US$56 million in 2024, as R&D and commercial investments ramped across its therapeutic and manufacturing platforms.